Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2017 - Deal Trends, Players, Financials and Forecasts - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players, financials and forecasts" report to their offering.

Global Cancer Monoclonal Antibody Partnering 2010 to 2017 provides the full collection of Cancer Monoclonal Antibody disease deals signed between the world's Cancer Monoclonal Antibody and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Cancer Monoclonal Antibody disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cancer Monoclonal Antibody deals.

Global Cancer Monoclonal Antibody Partnering 2010 to 2017 includes:

  • Trends in Cancer Monoclonal Antibody dealmaking in the biopharma industry since 2010
  • Analysis of Cancer Monoclonal Antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Cancer Monoclonal Antibody deal contract documents
  • Comprehensive access to Cancer Monoclonal Antibody deal records
  • The leading Cancer Monoclonal Antibody deals by value since 2010
  • Most active Cancer Monoclonal Antibody dealmakers since 2010

In Global Cancer Monoclonal Antibody Partnering 2010 to 2017, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Monoclonal Antibody dealmaking

Chapter 3 - Financial deal terms for Cancer Monoclonal Antibody partnering

Chapter 4 - Leading Cancer Monoclonal Antibody deals and dealmakers

Chapter 5 - Cancer Monoclonal Antibody contract document directory

Chapter 6 - Cancer Monoclonal Antibody dealmaking by therapeutic target

For more information about this report visit http://www.researchandmarkets.com/research/jmbtxq/global_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology, Oncology Drugs, Biopharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology, Oncology Drugs, Biopharmaceuticals